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Telomerase is a ribonucleoprotein
with the function of a DNA poly-
merase, in which a segment of the RNA
component operates as an internal tem-
plate. It adds hexameric (TTAGGG) re-
peats to the telomeric ends of the chro-
mosomes, thus compensating for the
continued erosion of the telomeres that
occurs in its absence (3,7). Reactivation
of telomerase might be a necessary
event for the sustained growth of most
human tumors (9). The development of
a polymerase chain reaction (PCR)-
based telomerase assay, the telomeric
repeat amplification protocol (TRAP),
has permitted a large number of tumor
samples to be analyzed (5).
Telomerase activity has been detect-
ed in almost all human immortal cell
lines and in most human cancer tissues
(2,5). However, some human tumor tis-
sues seem not to express telomerase. A
review that compiled several studies of
human tumors indicated that telo-
merase activity occurred in human can-
cer tissues in 75%–100% of cases, with
an average of 84.8% (8). Furthermore,
different studies on histologically simi-
lar tumors revealed different propor-
tions of tumors with telomerase activi-
ty. For example, in colorectal cancer,
telomerase activity was detected in 32
of 35 cases (92%) by Kim et al. (5), in
40 of 50 cases  (80%) by Li et al. (6)
and in 8 of 8 cases (100%) by Yoshida
et al. (11). An explanation for these dis-
crepancies could be heterogeneity of
human tumor tissues that invariably
consist of mixtures of tumor cells and
surrounding stromal tissue. However,
the TRAP assay has been shown to de-
tect telomerase activity in as few as 1
positive cell per 104 cells (5). We pro-
pose that some of the apparently nega-
tive tumors yield RNA of insufficient
quality and are therefore false negative. 
A second reason for false-negative
results might be the presence of Taq
DNA polymerase inhibitors. To recog-
nize this type of problem, the TRAP as-
say should be performed using an inter-
nal control (10). The TRAP-ezeÔ
Telomerase Detection Kit (Oncor,
Gaithersburg, MD, USA) includes the
amplification of an internal control of
36 bp in each assay, and a false-nega-
tive result is concluded when the 36-bp
amplified product is not observed. This
control, however, does not account for
all apparently negative tumor tissues.
Telomerase is a ribonucleoprotein
enzyme that uses its RNA as a template
for the synthesis of TTAGGG repeats at
the ends of the chromosomes (4). For
this reason, telomerase activity necessi-
tates an active protein and a nondegrad-
ed RNA. These two conditions indicate
that the quality of the tissue is of vital
importance for the success of the
telomerase detection assay. Strikingly,
RNA quality control has never been
proposed to date. We therefore includ-
ed a control for RNA quality in our
TRAP assay protocol.
We measured telomerase activity in
50 colorectal cancer tissues derived
from 50 patients using the TRAP assay.
About 10 mg of frozen tissue were ho-
mogenized in 150 mL of 1´ CHAPS ly-
sis buffer (5). The whole-tissue lysate
was rapidly frozen and stored at -80°C.
The protein concentrations of the ex-
tract were measured using the BCAÔ
Protein Assay Kit (Pierce Chemical,
Rockford, IL, USA). Approximately
0.1 mg of protein extracted from tissue
was used for each telomerase assay (25
mL reaction). Forty-two samples (84%)
were found to be positive in this assay,
while 8 samples were telomerase-nega-
tive. All 50 samples were taken from
the tissue bank of the Institute of  Path-
ology (Lausanne, Switzerland). Some
samples were not frozen immediately.
This lapse of time that occurred some-
times between surgery and freezing in
liquid nitrogen is relatively important.
Warm ischemia might account for tissue
autolysis including RNA degradation,
which can affect the telomerase activity
results. To test this hypothesis, total
RNA from these 50 colon cancer tissues
was extracted using TRIZOLÒ Reagent
(Life Technologies, Gaithersburg, MD,
USA). For each case, approximately 50
mg of frozen tissue were used to extract
RNA. The quality of RNA was con-
trolled on agarose gels (Figure 1A). In
25 out of 50 colon cancer tissues, the
RNA showed no or partial 28S and 18S
ribosomal RNA degradation (Figure
1A, lanes 3–6). In the other 25 cases,
significant to complete RNA degrada-
tion was observed (Figure 1A, lanes
7–9). All of the 25 cases with only par-
tially degraded or intact RNA showed
telomerase activity (Figure 1, A and C,
lanes 3–6). Only 17 of the 25 cases
(68%)  with strongly or completely de-
graded RNA were positive for telo-
merase activity (Figure 1, A and C,
lanes 7–9). This difference is statistical-
ly significant (P <0.0001). Various lev-
els of telomerase activity were ob-
served. All of the 25 cases with only
weak RNA degradation showed strong
telomerase activity (Figure 1C, lanes
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3–6), whereas most cases with strongly
degraded RNA had either weak (Figure
1C, lanes 7 and 8) or even no (Figure
1C, lanes 9 and 10) telomerase activity.
Most cases with complete RNA degra-
dation had no detectable telomerase ac-
tivity (Figure 1, A and C, lanes 9 and
10). The fact that telomerase activity
was observed in some cases with appar-
ent RNA degradation can be explained
on the assumption that the full length of
the RNA component of telomerase is
not necessary for telomerase activity
(1). Another explanation for the pres-
ence of telomerase activity in partially
degraded samples could be the sensitivi-
ty of the TRAP assay. Even a significant
reduction in the number of active telo-
merase molecules due to tissue degrada-
tion might not totally abolish detectable
telomerase activity in the sample.
A limitation of this approach is that
the amount of tissue required to per-
form an rRNA measurement is too high
for small biopsies. To overcome this
limitation, different approaches have
been tested. First, RNA quality was de-
termined directly from the RNA in tis-
sue extracts obtained from CHAPS ly-
sis buffer. Using TRIZOL, 5–10 mg of
total RNA were obtained from tissue
extracts (60 mg of protein extract).
Some rRNA degradation was observed
by agarose gel analysis, and in most
cases, no 28S and 18S rRNA bands
were observed. The same RNAs were
also analyzed by reverse transcription
(RT)-PCR using b-actin and glycer-
aldehyde 3-phosphate dehydrogenase
(GAPDH) as markers. Almost all cases
gave an amplification of b-actin and
GAPDH, even those in which telo-
merase activity was undetectable. RT-
PCR gave many false-positive results
and is therefore not a suitable method
to determine tissue quality. In another
approach, total RNA was extracted
from consecutive tissue sections. De-
pending on the size of the tissue sample
to analyze, 1–5 sections of 10 mM are
enough to extract cells in 30 mL of
CHAPS lysis buffer for telomerase
analysis, whereas 4–10 sections are
necessary for extraction of a sufficient
amount of RNA (total RNA dissolved
in 20 mL water). Using this approach,
the results for telomerase activity and
rRNA measurements are perfectly su-
perimposable with those obtained with
large amount of tissues (see Figure 1, A
and B, for rRNA quality). Furthermore,
sections for histological analysis can be
prepared just before and after the
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Table 1. Telomerase Activity and RNA Degra-
tion in Colorectal Cancer Tissues
RNAi RNAd
Telomerase+ 25 17
Telomerase- 0 8
RNAi: RNA intact or only partially
degraded
RNAd: high RNA degradation (28S
and 18S rRNA species completely
missing)
Figure 1. RNA quality and telomerase activity
in colorectal cancer tissues. (A and B) Total
RNA extracted from frozen colon cancer tissues
(A) and from tissue sections (B) was subjected to
1% agarose gel electrophroresis. Lanes 2–10 con-
tained about 0.6–1.0 mg of total RNA. (C) Telom-
erase activity was detected using the TRAP assay.
About 0.1 mg of protein extracted from frozen
colon cancer tissues was placed in 25 mL of PCR
mixture for each assay. One-fifth of the PCR am-
plification product was applied to a 12.5% non-
denaturing polyacrylamide gel and visualized by
SYBRÒ Green I (Molecular Probes, Eugene,
OR, USA) staining. Lane 1: pGEMÒ DNA
Marker (Promega, Madison, WI, USA). RNA
analysis (A and B) or telomerase assay (C) from
SW480 colorectal cancer cell line (lane 2) or
from frozen colorectal tumor tissues (lanes
3–10). Panel C, lane 11: negative control where
no protein was added. 
section necessary for telomerase and
RNA analysis. Thus, histological char-
acteristics of the analyzed lesions can
be correlated directly to telomerase ac-
tivity, and false-negative results due to
sampling error can be avoided.
These results indicate that if RNA is
not strongly or completely degraded
(28S and 18S rRNA species not com-
pletely missing), more reliable results
will be obtained. If RNA is strongly de-
graded, telomerase activity is not always
observed (Table 1). Our results clearly
indicate that for a valid TRAP assay, the
control of RNA quality is essential to re-
duce the number of false-negative re-
sults. This control is simple and rapid
and can be done in less than 2 h.
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